Your browser doesn't support javascript.
loading
A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis.
Gu, Ben J; Field, Judith; Dutertre, Sébastien; Ou, Amber; Kilpatrick, Trevor J; Lechner-Scott, Jeannette; Scott, Rodney; Lea, Rodney; Taylor, Bruce V; Stankovich, Jim; Butzkueven, Helmut; Gresle, Melissa; Laws, Simon M; Petrou, Steven; Hoffjan, Sabine; Akkad, Denis A; Graham, Colin A; Hawkins, Stanley; Glaser, Anna; Bedri, Sahl Khalid; Hillert, Jan; Matute, Carlos; Antiguedad, Alfredo; Wiley, James S.
Affiliation
  • Gu BJ; Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.
  • Field J; Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.
  • Dutertre S; Institut des Biomolécules Max Mousseron, UMR 5247, Université Montpellier 2-CNRS, Montpellier, France.
  • Ou A; Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.
  • Kilpatrick TJ; Melbourne Neuroscience Institute, University of Melbourne, Parkville, Victoria, Australia.
  • Lechner-Scott J; Hunter Medical Research Institute, The University of Newcastle, Newcastle, New South Wales, Australia.
  • Scott R; Hunter Medical Research Institute, The University of Newcastle, Newcastle, New South Wales, Australia.
  • Lea R; Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia.
  • Taylor BV; Menzies Institute, University of Tasmania, Hobart, Tasmania, Australia.
  • Stankovich J; Menzies Institute, University of Tasmania, Hobart, Tasmania, Australia.
  • Butzkueven H; Department of Medicine, University of Melbourne, Royal Melbourne Hospital, Parkville, Victoria, Australia.
  • Gresle M; Department of Medicine, University of Melbourne, Royal Melbourne Hospital, Parkville, Victoria, Australia.
  • Laws SM; School of Medical Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.
  • Petrou S; Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.
  • Hoffjan S; Department of Human Genetics, Ruhr-University Bochum, Bochum, Germany.
  • Akkad DA; Department of Human Genetics, Ruhr-University Bochum, Bochum, Germany.
  • Graham CA; Regional Genetics Laboratories, Belfast Health & Social Care Trust, Northern Ireland, UK.
  • Hawkins S; Department of Neurology, Belfast Health & Social Care Trust, Northern Ireland, UK.
  • Glaser A; Department of Clinical Neurosciences, Karolinska Institutet, Stockholm, Sweden.
  • Bedri SK; Department of Clinical Neurosciences, Karolinska Institutet, Stockholm, Sweden.
  • Hillert J; Department of Clinical Neurosciences, Karolinska Institutet, Stockholm, Sweden.
  • Matute C; CIBERNED, Achucarro Basque Center for Neuroscience, and Departamento de Neurociencias, Universidad del País Vasco, Leioa, Spain and.
  • Antiguedad A; Servicio de Neurología, Hospital Universitario Basurto-Osakidetza, Bilbao, Spain.
  • Wiley JS; Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia, james.wiley@florey.edu.au.
Hum Mol Genet ; 24(19): 5644-54, 2015 Oct 01.
Article in En | MEDLINE | ID: mdl-26188005
ABSTRACT
Multiple sclerosis (MS) is a chronic relapsing-remitting inflammatory disease of the central nervous system characterized by oligodendrocyte damage, demyelination and neuronal death. Genetic association studies have shown a 2-fold or greater prevalence of the HLA-DRB1*1501 allele in the MS population compared with normal Caucasians. In discovery cohorts of Australasian patients with MS (total 2941 patients and 3008 controls), we examined the associations of 12 functional polymorphisms of P2X7, a microglial/macrophage receptor with proinflammatory effects when activated by extracellular adenosine triphosphate (ATP). In discovery cohorts, rs28360457, coding for Arg307Gln was associated with MS and combined analysis showed a 2-fold lower minor allele frequency compared with controls (1.11% for MS and 2.15% for controls, P = 0.0000071). Replication analysis of four independent European MS case-control cohorts (total 2140 cases and 2634 controls) confirmed this association [odds ratio (OR) = 0.69, P = 0.026]. A meta-analysis of all Australasian and European cohorts indicated that Arg307Gln confers a 1.8-fold protective effect on MS risk (OR = 0.57, P = 0.0000024). Fresh human monocytes heterozygous for Arg307Gln have >85% loss of 'pore' function of the P2X7 receptor measured by ATP-induced ethidium uptake. Analysis shows Arg307Gln always occurred with 270His suggesting a single 307Gln-270His haplotype that confers dominant negative effects on P2X7 function and protection against MS. Modeling based on the homologous zP2X4 receptor showed Arg307 is located in a region rich in basic residues located only 12 Å from the ligand binding site. Our data show the protective effect against MS of a rare genetic variant of P2RX7 with heterozygotes showing near absent proinflammatory 'pore' function.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adenosine Triphosphate / Amino Acid Substitution / Receptors, Purinergic P2X7 / Multiple Sclerosis Type of study: Risk_factors_studies Limits: Humans Country/Region as subject: Oceania Language: En Journal: Hum Mol Genet Journal subject: BIOLOGIA MOLECULAR / GENETICA MEDICA Year: 2015 Type: Article Affiliation country: Australia

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adenosine Triphosphate / Amino Acid Substitution / Receptors, Purinergic P2X7 / Multiple Sclerosis Type of study: Risk_factors_studies Limits: Humans Country/Region as subject: Oceania Language: En Journal: Hum Mol Genet Journal subject: BIOLOGIA MOLECULAR / GENETICA MEDICA Year: 2015 Type: Article Affiliation country: Australia